reported a 55% increase in third-quarter profit, thanks to sales of its HIV drugs.
The California company had net income of $113.2 million, or 25 cents a share, compared to net income of $73.1 million, or 17 cents a share, a year ago.
Revenue rose 63% to $326.2 million.
Analysts expected the company to earn 21 cents a share, according to Thomson First Call.
HIV product sales were $228.1 million during the third quarter of 2004, up from $121.4 million.
Shares fell $1.13, or 3%, to $36.68 in after-hours trading.